Stakeholder preferences regarding Shigella vaccines

Shigella is the leading bacterial cause of childhood diarrhea, and infections can have long-term effects on growth and development. No licensed Shigella vaccines currently exist, but several promising candidates in development could become available in a few years.

PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. This included a multi-country feasibility and acceptability study with national stakeholders and healthcare providers in Burkina Faso, Ghana, Kenya, Nepal, and Vietnam to identify preferences and priorities for future Shigella vaccines. These briefs provide an overview of the results in each of the study countries.

Corporate author(s): PATH

Publication date: November 2022

Available materials

  1. English

    1. Stakeholder preferences regarding Shigella vaccines in Burkina Faso 499.7 KB PDF
    2. Stakeholder preferences regarding Shigella vaccines in Ghana 494 KB PDF
    3. Stakeholder preferences regarding Shigella vaccines in Kenya 502.9 KB PDF
    4. Stakeholder preferences regarding Shigella vaccines in Nepal 442.4 KB PDF
    5. Stakeholder preferences regarding Shigella vaccines in Vietnam 413.6 KB PDF

  2. French

    1. Préférences des parties prenantes concernant les vaccins contre la shigellose au Burkina Faso 497.4 KB PDF

  3. Nepali

    1. Stakeholder preferences regarding Shigella vaccines in Nepal [Nepali version] 646 KB PDF

  4. Vietnamese

    1. Tham vấn các bên liên quan về vắc xin Ngừa Lỵ trực trùng tại Việt Nam 384 KB PDF